| Name | Title | Contact Details |
|---|---|---|
Kelly Smith |
VP of RandD | Profile |
Ashley Jenkins |
CFO | Profile |
Nohla Therapeutics is a cellular therapy company driven to provide leading off the shelf therapies for patients with critical diseases. Nohla’s first product is a universal donor cell therapy targeting hematopoietic recovery and chemotherapy induced neutropenia, and is being extended to treat a range of other medical indications. This and other products in the pipeline are based on a unique umbilical cord blood expansion platform developed at the Fred Hutchinson Cancer Research Center
Caladrius is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of cell therapies designed to reverse disease and/or promote the regeneration of damaged tissue. The Company is developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. The Company`s platform technology leverages these cells to enable the body`s natural repair mechanisms using formulations unique to each medical indication.
MediGene, Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Palvella Therapeutics was founded with the single-minded goal of serving individuals suffering from serious rare genetic diseases with no approved treatments.
Q-Chuck Technologies Inc. is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.